NCT02530710View on ClinicalTrials.gov

A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Doses of Q203 in Normal, Healthy, Male and Female Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

January 31, 2016

Study Completion Date

July 31, 2016

Conditions
Healthy Volunteers
Interventions
DRUG

Q203

DRUG

Placebo

Trial Locations (1)

21225

Baltimore

All Listed Sponsors
lead

Qurient Co., Ltd.

INDUSTRY

NCT02530710 - A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Doses of Q203 in Normal, Healthy, Male and Female Volunteers | Biotech Hunter | Biotech Hunter